CG Oncology CGON Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.07M+25.5% | $4.04M+85.8% | $2.17M+295% | $551K-16.8% | $662K-41.9% | ||
| $132.9M+13.9% | $116.64M+2.8% | $113.48M+7.9% | $105.22M+13.9% | $92.36M+12.5% | ||
| $79.52M+8.1% | $73.53M+9.4% | $67.24M+27.8% | $52.62M+23.2% | $42.7M+26.7% | ||
| $220.03M+12.9% | $194.81M+6.9% | $182.3M+15.5% | $157.84M— | —— | ||
| -$214.96M-12.7% | -$190.77M-5.9% | -$180.12M-14.5% | -$157.29M-17.0% | -$134.4M-17.2% | ||
| -4,239%+483pp | -4,722.1%+3,563pp | -8,285.3%+20,261pp | -28,546.1%-8,244pp | -20,302.3%-10,235pp | ||
| $28.21M-5.3% | $29.78M+4.0% | $28.64M-1.9% | $29.21M+1.3% | $28.84M+8.3% | ||
| -$186.75M-16.0% | -$161M-6.3% | -$151.48M-18.3% | -$128.08M-21.3% | -$105.56M-19.9% | ||
| -3,682.6%+302pp | -3,985%+2,983pp | -6,968%+16,277pp | -23,245.2%-7,300pp | -15,945.2%-8,216pp | ||
| -$2.33-12.6% | -$2.07-1.5% | -$2.04-15.3% | -$1.77-17.2% | -$1.51-6.3% | ||
| -$212.7M-12.3% | -$189.33M-5.5% | -$179.53M-14.3% | -$157.09M-16.9% | -$134.35M-17.2% | ||
| -4,194.4%+492pp | -4,686.4%+3,572pp | -8,257.9%+20,252pp | -28,509.6%-8,215pp | -20,294.4%-10,230pp | ||
| -$214.96M-12.7% | -$190.77M-5.9% | -$180.12M-14.5% | -$157.29M-17.0% | -$134.4M-17.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CG Oncology's income statement data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.